SG11202103796TA - Indole ahr inhibitors and uses thereof - Google Patents
Indole ahr inhibitors and uses thereofInfo
- Publication number
- SG11202103796TA SG11202103796TA SG11202103796TA SG11202103796TA SG11202103796TA SG 11202103796T A SG11202103796T A SG 11202103796TA SG 11202103796T A SG11202103796T A SG 11202103796TA SG 11202103796T A SG11202103796T A SG 11202103796TA SG 11202103796T A SG11202103796T A SG 11202103796TA
- Authority
- SG
- Singapore
- Prior art keywords
- compound
- cancer
- ring
- pharmaceutically acceptable
- vii
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862746277P | 2018-10-16 | 2018-10-16 | |
| PCT/US2019/056455 WO2020081636A1 (en) | 2018-10-16 | 2019-10-16 | Indole ahr inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103796TA true SG11202103796TA (en) | 2021-05-28 |
Family
ID=70284697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103796TA SG11202103796TA (en) | 2018-10-16 | 2019-10-16 | Indole ahr inhibitors and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220144839A1 (enExample) |
| EP (1) | EP3867253A4 (enExample) |
| JP (1) | JP2022502476A (enExample) |
| KR (1) | KR20210110566A (enExample) |
| CN (1) | CN113272305A (enExample) |
| AU (1) | AU2019360204A1 (enExample) |
| BR (1) | BR112021007017A2 (enExample) |
| CA (1) | CA3115711A1 (enExample) |
| EA (1) | EA202190726A1 (enExample) |
| IL (1) | IL282252A (enExample) |
| MX (1) | MX2021004245A (enExample) |
| SG (1) | SG11202103796TA (enExample) |
| WO (1) | WO2020081636A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019012431A (es) | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
| AU2020394424A1 (en) | 2019-11-26 | 2022-06-16 | Ikena Oncology, Inc. | Polymorphic carbazole derivatives and uses thereof |
| BR112022013673A2 (pt) | 2020-01-10 | 2022-09-13 | Ikena Oncology Inc | Inibidores de ahr e seus usos |
| WO2021236717A1 (en) | 2020-05-20 | 2021-11-25 | Senda Biosciences, Inc. | Fused imidazole derivatives as ahr antagonists |
| CA3182093A1 (en) * | 2020-06-10 | 2021-12-16 | Florence Wagner | Tricyclic psychoplastogens and uses thereof |
| CN114369097B (zh) * | 2020-10-15 | 2023-07-14 | 山东轩竹医药科技有限公司 | 杂芳环类AhR抑制剂 |
| CA3196535A1 (en) * | 2020-10-28 | 2022-05-05 | Alfredo C. Castro | Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine |
| US12540141B2 (en) | 2020-11-23 | 2026-02-03 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2022109360A1 (en) | 2020-11-23 | 2022-05-27 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| CN114456178B (zh) * | 2021-01-13 | 2023-06-02 | 北京华森英诺生物科技有限公司 | 四氢嘧啶[1,2-b]吲唑-4-胺类衍生物作为AhR抑制剂的用途及制备方法 |
| CN114805361B (zh) * | 2021-01-17 | 2024-02-20 | 上海凌达生物医药有限公司 | 一类氨基取代的芳香杂环并吡唑类化合物、制备方法和用途 |
| US11970502B2 (en) | 2021-05-04 | 2024-04-30 | Enanta Pharmaceuticals, Inc. | Macrocyclic antiviral agents |
| WO2023086352A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| US11858945B2 (en) | 2021-11-12 | 2024-01-02 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
| WO2023086400A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| US11993600B2 (en) | 2021-12-08 | 2024-05-28 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
| US12006291B2 (en) | 2022-01-11 | 2024-06-11 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 4,6,7-trifluoro-1H-indole-2-carboxylic acid |
| US12145942B2 (en) | 2022-04-05 | 2024-11-19 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| EP4504341A1 (en) | 2022-04-08 | 2025-02-12 | Shy Therapeutics LLC | Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| CN117624168A (zh) * | 2022-08-19 | 2024-03-01 | 德明药泰生物技术（深圳）有限公司 | 稠环杂环类化合物及其制备方法和应用 |
| EP4617262A1 (en) | 2022-11-07 | 2025-09-17 | Kyoto University | Nitrogen-containing heterocyclic compound |
| KR20240169284A (ko) | 2023-05-24 | 2024-12-03 | 경희대학교 산학협력단 | AhR-매개 질환의 예방, 개선 또는 치료용 약학적 조성물 |
| WO2025114771A1 (en) | 2023-11-29 | 2025-06-05 | Latvian Institute Of Organic Synthesis | A new class of aryl hydrocarbon receptor antagonists and their optimisation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721356A (en) * | 1989-09-15 | 1998-02-24 | Gensia, Inc. | Orally active adenosine kinase inhibitors |
| JP4895806B2 (ja) * | 2003-04-09 | 2012-03-14 | エクセリクシス， インク． | Ｔｉｅ−２モジュレータと使用方法 |
| TW200536536A (en) * | 2004-02-25 | 2005-11-16 | Schering Corp | Pyrazolotriazines as kinase inhibitors |
| PE20100362A1 (es) * | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| CN108290855A (zh) * | 2015-07-01 | 2018-07-17 | 西北大学 | 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途 |
| US20180072741A1 (en) * | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| MX2019012431A (es) * | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
-
2019
- 2019-10-16 KR KR1020217014753A patent/KR20210110566A/ko not_active Withdrawn
- 2019-10-16 WO PCT/US2019/056455 patent/WO2020081636A1/en not_active Ceased
- 2019-10-16 SG SG11202103796TA patent/SG11202103796TA/en unknown
- 2019-10-16 EP EP19873025.1A patent/EP3867253A4/en not_active Withdrawn
- 2019-10-16 CN CN201980076086.7A patent/CN113272305A/zh active Pending
- 2019-10-16 US US17/281,395 patent/US20220144839A1/en not_active Abandoned
- 2019-10-16 CA CA3115711A patent/CA3115711A1/en active Pending
- 2019-10-16 AU AU2019360204A patent/AU2019360204A1/en not_active Abandoned
- 2019-10-16 BR BR112021007017-6A patent/BR112021007017A2/pt not_active IP Right Cessation
- 2019-10-16 JP JP2021521024A patent/JP2022502476A/ja active Pending
- 2019-10-16 EA EA202190726A patent/EA202190726A1/ru unknown
- 2019-10-16 MX MX2021004245A patent/MX2021004245A/es unknown
-
2021
- 2021-04-12 IL IL282252A patent/IL282252A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021004245A (es) | 2021-09-08 |
| US20220144839A1 (en) | 2022-05-12 |
| CA3115711A1 (en) | 2020-04-23 |
| EP3867253A1 (en) | 2021-08-25 |
| JP2022502476A (ja) | 2022-01-11 |
| CN113272305A (zh) | 2021-08-17 |
| IL282252A (en) | 2021-05-31 |
| WO2020081636A1 (en) | 2020-04-23 |
| AU2019360204A1 (en) | 2021-06-03 |
| KR20210110566A (ko) | 2021-09-08 |
| BR112021007017A2 (pt) | 2021-07-13 |
| EP3867253A4 (en) | 2022-05-18 |
| EA202190726A1 (ru) | 2021-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282252A (en) | Indole AHR inhibitors and their uses | |
| IL282487B1 (en) | Tyk2 inhibitors and their use | |
| IL272649B (en) | AHR inhibitors and their uses | |
| IL276147A (en) | GCN2 inhibitors and uses thereof | |
| IL271999A (en) | TYK2 inhibitors and uses thereof | |
| IL276095A (en) | gcn2 inhibitors and their uses | |
| IL283409A (en) | tyk2 inhibitors and uses thereof | |
| IL282090B2 (en) | TYK2 inhibitors and their uses | |
| IL268619B (en) | Piperidine-converted mnk inhibitors and related methods | |
| IL282350A (en) | Bernani-RGMC inhibitors and their use | |
| IL280051A (en) | EP4 inhibitors and their synthesis | |
| PT3621694T (pt) | Inibidores de lrrc33 e sua utilização | |
| IL276013A (en) | pi4kiiibeta inhibitors | |
| IL280408A (en) | CDK inhibitors and uses thereof | |
| GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
| HK40058976A (en) | Indole ahr inhibitors and uses thereof | |
| HK40023946A (en) | Indole ahr inhibitors and uses thereof | |
| HK40026667A (en) | Ahr inhibitors and uses thereof | |
| HK40078624A (en) | Ahr inhibitors and uses thereof | |
| GB201908884D0 (en) | Inhibitors and use | |
| GB201812462D0 (en) | Inhibitors | |
| GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors |